Wave Life Sciences (WVE) Accounts Payables (2014 - 2026)

Wave Life Sciences (WVE) has 13 years of Accounts Payables data on file, last reported at $20.4 million in Q2 2026.

• Quarterly Accounts Payables rose 38.86% year-over-year to $20.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.4 million (up 38.86% YoY) and the FY2025 annual result came in at $15.7 million, down 3.46% from the prior year.
• Accounts Payables rose to $20.4 million in Q2 2026, from $19.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $20.4 million in Q2 2026 to a low of $9.9 million in Q1 2022.
• A 5-year average of $14.5 million and a median of $14.4 million in 2025 frame the typical range for Accounts Payables.
• The widest YoY moves for Accounts Payables: up 132.32% in 2022, down 26.57% in 2022.
• Tracing WVE's Accounts Payables over 5 years: stood at $16.9 million in 2022, then declined by 24.1% to $12.8 million in 2023, then advanced by 26.66% to $16.3 million in 2024, then decreased by 3.46% to $15.7 million in 2025, then gained by 29.69% to $20.4 million in 2026.
• The last three Accounts Payables figures came in at $20.4 million (Q2 2026), $19.1 million (Q1 2026), and $15.7 million (Q4 2025), per Business Quant data.